Clinical Trial: Study of LT-010391 in Participants With KRAS G12D-Mutant Solid Tumors

U.S., June 4 -- ClinicalTrials.gov registry received information related to the study (NCT07624214) titled 'Study of LT-010391 in Participants With KRAS G12D-Mutant Solid Tumors' on May 24.

Brief Summary: This study is to evaluate the safety and tolerability of of LT-010391 as monotherapy in participants with KRAS G12D mutant advanced solid tumors

Study Start Date: July, 2026

Study Type: INTERVENTIONAL

Condition: Non-small Cell Lung Cancer (NSCLC) Colorectal Cancer (CRC) Pancreatic Ductal Adenocarcinoma (PDAC) Advanced Solid Tumors

Intervention: DRUG: LT-010391

LT-010391 tablets, oral, once daily

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.

Published by HT Digital Content Services...